Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
insulin + propranolol
- Development stage
- Unknown
- Lead developer
- Novo Nordisk
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Subcutaneous, Oral, Intravenous
01
Overview
A combination of insulin and propranolol. Insulin is a hormone used to treat diabetes mellitus by promoting glucose uptake from the blood into cells. Propranolol is a non-selective beta-adrenergic antagonist (beta-blocker) used to treat various conditions including hypertension, angina, atrial fibrillation, and migraines. When used together, propranolol may increase the risk, severity, and duration of hypoglycemia in patients receiving insulin by masking some warning signs of low blood sugar and potentially enhancing insulin's blood-glucose-lowering effects.
02
Targets
INSR (Insulin receptor)SOX18ADRB2 (β2)ADRB3 (β3)ADRB1 (β1)
Beyond the preview
Go deeper on insulin + propranolol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on insulin + propranolol.